Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Veracyte, Inc.    VCYT

VERACYTE, INC.

(VCYT)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
12/02/2019 12/03/2019 12/04/2019 12/05/2019 12/06/2019 Date
27.19(c) 26.26(c) 28.345(c) 29.99(c) 29.18(c) Last
722 519 1 362 846 996 736 904 034 527 043 Volume
-5.33% -3.42% +7.94% +5.80% -2.70% Change
More quotes
Financials (USD)
Sales 2019 120 M
EBIT 2019 -11,2 M
Net income 2019 -8,91 M
Finance 2019 197 M
Yield 2019 -
Sales 2020 136 M
EBIT 2020 -12,3 M
Net income 2020 -10,4 M
Finance 2020 194 M
Yield 2020 -
P/E ratio 2019 -151x
P/E ratio 2020 -138x
EV / Sales2019 10,2x
EV / Sales2020 9,03x
Capitalization 1 425 M
More Financials
Company
Veracyte, Inc. is a genomic diagnostics company. The Company, through its scientific platform, which utilizes ribonucleic acid (RNA), whole-transcriptome sequencing combined with machine learning, produces genomic tests. It provides various genomic tests, including Afirma Genomic Sequencing... 
More about the company
Surperformance© ratings of Veracyte, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on VERACYTE, INC.
12/03VERACYTE, INC. : Entry into a Material Definitive Agreement, Completion of Acqui..
AQ
12/03VERACYTE : Acquires Exclusive License to NanoString Diagnostics Platform, Positi..
BU
11/02VERACYTE : Announces New Data That Advance Understanding of Genomic Alterations ..
BU
10/30VERACYTE : Announces New Data Characterizing Genomic Alterations in Thyroid Canc..
BU
10/22VERACYTE : 3Q Earnings Snapshot
AQ
10/22VERACYTE : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESUL..
AQ
10/22VERACYTE, INC. : Results of Operations and Financial Condition, Financial Statem..
AQ
10/22VERACYTE : Announces Third Quarter 2019 Financial Results and Business Progress
BU
10/22VERACYTE : Announces New Clinical Data Showing First-Ever Noninvasive Nasal Swab..
BU
10/21VERACYTE : Announces Clinical Data Demonstrating Clinical Validity and Utility o..
BU
10/21VERACYTE : Announces New Data Demonstrating That Envisia Genomic Classifier Impr..
BU
10/08VERACYTE : to Release Third Quarter 2019 Financial Results and Business Progress..
BU
10/07VERACYTE : to Announce New Clinical Data for First Noninvasive Nasal Swab Test t..
PU
09/11VERACYTE : Announces Publication of Clinical and Analytical Validation Data for ..
BU
09/03VERACYTE : Announces Publication of New Study Characterizing Gene Alterations in..
BU
More news
News in other languages on VERACYTE, INC.

- No features available -

More news
Sector news : Bio Diagnostics & Testing
12/06Glencore Faces U.K. Bribery Probe -- WSJ
DJ
12/05REGENERON PHARMACEUTICALS : Reports Positive Phase 2 Data for Pozelimab in PNH
DJ
12/04Glencore to Change 'Old Guard' Ahead Of CEO Transition -- WSJ
DJ
11/28Novartis's $90 million Swiss factory to help solve cell therapy bottleneck
RE
11/28China's major shareholders sell A-shares, pressuring markets
RE
More sector news : Bio Diagnostics & Testing
Chart VERACYTE, INC.
Duration : Period :
Veracyte, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VERACYTE, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Average target price 34,00  $
Last Close Price 29,18  $
Spread / Highest target 19,9%
Spread / Average Target 16,5%
Spread / Lowest Target 13,1%
EPS Revisions
Managers
NameTitle
Bonnie H. Anderson Chairman & Chief Executive Officer
Keith Kennedy Chief Operating & Financial Officer
Giulia C. Kennedy Chief Scientific & Medical Officer
Ashish Kheterpal Chief Information Officer
Fred E. Cohen Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
VERACYTE, INC.131.96%1 425
GUARDANT HEALTH, INC.96.81%6 947
GENSCRIPT BIOTECH CORPORATION87.81%4 694
IOVANCE BIOTHERAPEUTICS, INC.179.32%3 120
INVITAE CORPORATION59.95%1 707
MIRACA HOLDINGS INC.11.27%1 418